Form 4: Camp4 Therapeutics Director Richard Young Reports Conversion of Preferred Stock to Common Stock

Director Richard Young reports the automatic conversion of Series A Prime Convertible Preferred Stock into Common Stock following Camp4 Therapeutics' initial public offering.

Summary

• On October 15, 2024, Richard A Young, a director of Camp4 Therapeutics Corp, reported the conversion of Series A Prime Convertible Preferred Stock into Common Stock.
• The conversion occurred automatically upon the closing of the Issuer's initial public offering.
• A total of 100,014 shares of Series A Prime Convertible Preferred Stock were converted into 8,917 shares of Common Stock, based on a conversion ratio of 11.2158-for-1.
• Following the transaction, Young directly owns 154,859 shares of Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (conversion of preferred stock to common stock after an IPO) and doesn't inherently indicate positive or negative sentiment, but the director's confidence in the company is a positive sign.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following its IPO.
• A director converting preferred stock to common stock signals confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are standard practice for company insiders reporting transactions in their company's securities, providing transparency to the market.

Stakeholder Impact

• The conversion simplifies the capital structure, potentially making the company more attractive to investors.
• The director's actions may influence investor confidence.

Key Dates